Загрузка...
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
BACKGROUND: Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union. METHODS: This 3-year follow-up study assessed the durability of sustained virologic response (SVR) (undetectable HC...
Сохранить в:
| Опубликовано в: : | Virol J |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5789677/ https://ncbi.nlm.nih.gov/pubmed/29378602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12985-018-0936-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|